prikaz prve stranice dokumenta A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?
  Download
PDF 175.73 KB
Scientific paper - Other
A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?
Annals of Translational Medicine, 4 (2016), 9; 162. https://doi.org/10.21037/atm.2016.04.15
Sreter, Katherina-Bernadette; Jakopovic, Marko; Janevski, Zoran; Samarzija, Miroslav; Zarogoulidis, Paul; Kioumis, Ioannis; Mparmpetakis, Nikolaos; Pataka, Athanasia; Zarogoulidis, Konstantinos; Tsiouda, Theodora; Kosmidis, Christoforos; Mpaka, Sofia; Huang, Haidong; Hohenforst-Schmidt, Wolfgang; Charalampidis, Charalampos; Machairiotis, Nikolaos; Zaric, Bojan; Milovancev, Aleksandar More authors...

Cite this document

Sreter, K. B., Jakopovic, M., Janevski, Z., Samarzija, M., Zarogoulidis, P., Kioumis, I. ... Milovancev, A. (2016). A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?. Annals of Translational Medicine, 4. (9). doi: 10.21037/atm.2016.04.15

Sreter, Katherina Bernadette, et al. "A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?." Annals of Translational Medicine, vol. 4, no. 9, 2016. https://doi.org/10.21037/atm.2016.04.15

Sreter, Katherina Bernadette, Marko Jakopovic, Zoran Janevski, Miroslav Samarzija, Paul Zarogoulidis, Ioannis Kioumis, Nikolaos Mparmpetakis, et al. "A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?." Annals of Translational Medicine 4, no. 9 (2016). https://doi.org/10.21037/atm.2016.04.15

Sreter, K. B., et al. (2016) 'A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?', Annals of Translational Medicine, 4(9). doi: 10.21037/atm.2016.04.15

Sreter KB, Jakopovic M, Janevski Z, Samarzija M, Zarogoulidis P, Kioumis I, and sur.. A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?. Annals of Translational Medicine [Internet]. 2016 May [cited 2024 November 17];4(9). doi: 10.21037/atm.2016.04.15

K. B. Sreter, et al., "A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?", Annals of Translational Medicine, vol. 4, no. 9, May 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:931880. [Accessed: 17 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?
AuthorKatherina-Bernadette Sreter
AuthorMarko Jakopovic
AuthorZoran Janevski
AuthorMiroslav Samarzija
AuthorPaul Zarogoulidis
AuthorIoannis Kioumis
AuthorNikolaos Mparmpetakis
AuthorAthanasia Pataka
AuthorKonstantinos Zarogoulidis
AuthorTheodora Tsiouda
AuthorChristoforos Kosmidis
AuthorSofia Mpaka
AuthorHaidong Huang
AuthorWolfgang Hohenforst-Schmidt
AuthorCharalampos Charalampidis
AuthorNikolaos Machairiotis
AuthorBojan Zaric
AuthorAleksandar Milovancev
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Background: Lung cancer is the leading cause of malignant pleural effusion (MPE). Management of MPEs remains a clinical challenge due to recurrence and poor quality of life. An ideal sclerosing agent has yet to be found. The aim of this cohort pilot study was to evaluate the role of mitoxantrone pleurodesis (MP) as an alternative to talc sclerotherapy for managing MPEs in lung cancer patients. Methods: A retrospective chart review was conducted on consecutively admitted patients with MPE to the Department of Post-Intensive Care at the Clinic for Respiratory Diseases “Jordanovac”, University Hospital Centre Zagreb, in Croatia. Results: Of 34 patients with MPE, twenty-one (64.8±9.46 years; 47–84 years) with primary lung carcinoma who received MP (30 mg of mitoxantrone) between December 2003 and February 2009 were included in this study. Chest radiographs taken prior to sclerotherapy and at 1-, 2-, and 3-month follow-up were compared. At the post-sclerotherapy evaluation periods, overall success (OS) rates of MP were 88.2% [17.6%, complete response (CR); 70.6%, partial response (PR)], 53.9% (7.7% CR; 46.2% PR), and 45.5% (PR), respectively. Kaplan-Meier median survival from MP until death was 5.2 months, while that from diagnosis of primary lung cancer was 12.3 months. Conclusions: MP may be a safe and effective method of managing MPE due to lung cancer. Future randomized controlled studies comparing mitoxantrone and talc pleurodesis in lung cancer patients are warranted to elucidate whether a significant difference exists between these agents. Factors affecting success, survival probability, and quality of life also require further investigation.
Keywords (english)
Languageenglish
Publication typeScientific paper - Other
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleAnnals of Translational Medicine
Numberingvol. 4, no. 9, 162
p-ISSN2305-5839
e-ISSN2305-5847
DOIhttps://doi.org/10.21037/atm.2016.04.15
URN:NBNurn:nbn:hr:220:931880
Publication2016-05
Document URLhttp://atm.amegroups.com/article/view/10302/11041
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2024-09-20 11:12:40